Cipla Ltd (CIPL.BO)

CIPL.BO on Bombay Stock Exchange

631.40INR
3:45pm IST
Change (% chg)

Rs4.85 (+0.77%)
Prev Close
Rs626.55
Open
Rs626.55
Day's High
Rs638.90
Day's Low
Rs626.55
Volume
77,724
Avg. Vol
194,696
52-wk High
Rs752.45
52-wk Low
Rs425.90

CIPL.BO

Chart for CIPL.BO

About

Cipla Limited (Cipla) is an India-based global pharmaceutical company. The Company’s portfolio includes approximately 2000 products in 65 therapeutic categories with one quality standard globally. Cipla’s turnover in 2012/13 was approximately 1.5 billion USD. The Company’s research and development focus on developing products... (more)

Overall

Beta: 0.49
Market Cap(Mil.): Rs509,882.50
Shares Outstanding(Mil.): 803.09
Dividend: 2.00
Yield (%): 0.32

Financials

  CIPL.BO Industry Sector
P/E (TTM): 43.23 35.34 39.54
EPS (TTM): 14.69 -- --
ROI: 11.18 17.03 16.22
ROE: 11.33 17.94 17.36
Search Stocks

INTERVIEW-India's Cipla expects to double respiratory drug sales by 2020

MUMBAI, June 17 - Indian generic drugmaker Cipla expects sales from its respiratory portfolio to more than double by 2020 and remains on track to launch its potentially lucrative inhaler in Britain, its chief executive said.

17 Jun 2015

India's Cipla expects to double respiratory drug sales by 2020

MUMBAI - Indian generic drugmaker Cipla expects sales from its respiratory portfolio to more than double by 2020 and remains on track to launch its potentially lucrative inhaler in Britain, its chief executive said.

17 Jun 2015

Interview - Cipla expects to double respiratory drug sales by 2020

MUMBAI - Generic drugmaker Cipla expects sales from its respiratory portfolio to more than double by 2020 and remains on track to launch its potentially lucrative inhaler in Britain, its chief executive said.

17 Jun 2015

INTERVIEW-India's Cipla expects to double respiratory drug sales by 2020

* Says plans to enter Latin America, Eastern Europe (Adds detail, fresh CEO comments)

17 Jun 2015

India's Cipla to sharpen focus on emerging markets in growth push

MUMBAI, June 17 - Cipla Ltd, India's fourth-largest drugmaker by sales, is planning to enter Latin America and Eastern Europe to tap into growing demand for generic drugs in emerging markets, Chief Executive Subhanu Saxena said.

17 Jun 2015

Lupin, Cipla bid for UCB's U.S. generic drugs portfolio - Bloomberg

MUMBAI - Generic drugmakers Lupin Ltd and Cipla Ltd are among the companies bidding for top Belgian drugmaker UCB SA's U.S. generic drugs business, Bloomberg reported on Monday, citing unnamed people with knowledge of the matter.

01 Jun 2015

India's Lupin, Cipla bid for UCB's US generic drugs portfolio - Bloomberg

MUMBAI, June 1 - Indian generic drugmakers Lupin Ltd and Cipla Ltd are among the companies bidding for top Belgian drugmaker UCB SA's U.S. generic drugs business, Bloomberg reported on Monday, citing unnamed people with knowledge of the matter.

01 Jun 2015

BUZZ-Investors take tactical refuge in Indian pharma ahead of Fed

** Pharmaceutical stocks, traditionally seen as defensives, gain on churning ahead of the U.S. Federal Reserve policy meeting outcome on Wednesday

17 Mar 2015

Germany's Boehringer loses India patent on lung drug to Cipla

MUMBAI - India has revoked a patent on German pharmaceutical company Boehringer Ingelheim's lung drug Spiriva and ruled in favour of domestic drugmaker Cipla Ltd, in the latest setback for a multinational drugmaker operating in India.

10 Mar 2015

Germany's Boehringer loses India patent on lung drug to Cipla

MUMBAI, March 10 - India has revoked a patent on German pharmaceutical company Boehringer Ingelheim's lung drug Spiriva and ruled in favour of domestic drugmaker Cipla Ltd , in the latest setback for a multinational drugmaker operating in India.

10 Mar 2015

Earnings vs. Estimates

Search Stocks